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BACKGROUND
Data on the effect of initial combination therapy with ambrisentan and tadalafil on 
long-term outcomes in patients with pulmonary arterial hypertension are scarce.
METHODS
In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, 
participants with World Health Organization functional class II or III symptoms of 
pulmonary arterial hypertension who had not previously received treatment to re-
ceive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil 
(combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentan-
monotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy 
group), all administered once daily. The primary end point in a time-to-event analy-
sis was the first event of clinical failure, which was defined as the first occurrence 
of a composite of death, hospitalization for worsening pulmonary arterial hyper-
tension, disease progression, or unsatisfactory long-term clinical response.
RESULTS
The primary analysis included 500 participants; 253 were assigned to the combina-
tion-therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the 
tadalafil-monotherapy group. A primary end-point event occurred in 18%, 34%, and 
28% of the participants in these groups, respectively, and in 31% of the pooled-
monotherapy group (the two monotherapy groups combined). The hazard ratio for 
the primary end point in the combination-therapy group versus the pooled-mono-
therapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001). At week 
24, the combination-therapy group had greater reductions from baseline in N-termi-
nal pro–brain natriuretic peptide levels than did the pooled-monotherapy group 
(mean change, −67.2% vs. −50.4%; P<0.001), as well as a higher percentage of pa-
tients with a satisfactory clinical response (39% vs. 29%; odds ratio, 1.56 [95% CI, 
1.05 to 2.32]; P = 0.03) and a greater improvement in the 6-minute walk distance 
(median change from baseline, 48.98 m vs. 23.80 m; P<0.001). The adverse events 
that occurred more frequently in the combination-therapy group than in either mono-
therapy group included peripheral edema, headache, nasal congestion, and anemia.
CONCLUSIONS
Among participants with pulmonary arterial hypertension who had not received 
previous treatment, initial combination therapy with ambrisentan and tadalafil 
resulted in a significantly lower risk of clinical-failure events than the risk with 
ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and Glaxo-
SmithKline; AMBITION ClinicalTrials.gov number, NCT01178073.)
A BS TR AC T
Initial Use of Ambrisentan plus Tadalafil  
in Pulmonary Arterial Hypertension
N. Galiè, J.A. Barberà, A.E. Frost, H.-A. Ghofrani, M.M. Hoeper, V.V. McLaughlin, 
A.J. Peacock, G. Simonneau, J.-L. Vachiery, E. Grünig, R.J. Oudiz, 
A. Vonk-Noordegraaf, R.J. White, C. Blair, H. Gillies, K.L. Miller, J.H.N. Harris, 
J. Langley, and L.J. Rubin, for the AMBITION Investigators* 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAT DE BARCELONA CRAI on October 16, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;9 nejm.org August 27, 2015 835
Ambrisentan–Tadalafil in Pulmonary Arterial Hypertension
Regardless of the initiating trig-ger, pulmonary arterial hypertension re-sults in the altered synthesis of a variety 
of vasoactive substances derived from the endo-
thelium.1 Current therapies for pulmonary arte-
rial hypertension2 target abnormalities in one of 
three intracellular pathways with signaling dys-
function: the prostacyclin, nitric oxide, or endo-
thelin pathway.1 However, no single class of drug 
is consistently effective in treating all patients, 
which suggests that no single pathway plays a 
dominant pathogenic role.3,4
Combination therapy with agents that target 
several different pathways may potentially in-
crease the overall therapeutic effect on the mech-
anisms of this disease5 and provide additional 
clinical benefits.6-14 Most previous clinical stud-
ies that have investigated combination therapy 
for pulmonary arterial hypertension have evalu-
ated sequential add-on therapies.6-14 The effects 
of initial combination therapy on long-term clini-
cal outcomes in patients who have not previously 
received treatment are unknown.10,15,16
The Ambrisentan and Tadalafil in Patients with 
Pulmonary Arterial Hypertension (AMBITION) 
trial investigated the efficacy and safety of ini-
tial combination therapy with oral, once-daily 
ambrisentan and tadalafil, as compared with 
monotherapy with either of these agents, in par-
ticipants with previously untreated pulmonary 
arterial hypertension. We chose this combination 
because ambrisentan,17 a selective endothelin-A–
receptor antagonist, and tadalafil,18 a phosphodi-
esterase type 5 inhibitor, target different intracel-
lular pathways and do not have pharmacokinetic 
interactions.19
Me thods
Study Design and Oversight
The AMBITION trial was a multicenter, random-
ized, double-blind, phase 3–4 study. The study 
was conducted between October 18, 2010 (first 
visit), and July 31, 2014 (last study visit), at 120 
centers in 14 countries (the full list of centers 
and investigators is provided in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). The trial protocol was de-
signed by the authors and the sponsors (Gilead 
Sciences in the United States and GlaxoSmith-
Kline in Canada, Europe, Japan, and Australia). 
The institutional review board at each center 
approved the study protocol. The monitoring 
and collection of the data were performed or 
overseen by the sponsors. The data were collected 
in electronic case-report forms, which were re-
tained by the sponsors, with copies sent to the 
principal investigator at each site. A clinical end-
point committee, whose members were unaware 
of the study-group assignments and of the iden-
tity of the investigator, adjudicated all reported 
clinical events. Statistical analysis, which was 
performed by personnel at Hartington Statistics 
and Data Management, was funded and overseen 
by the sponsors.
All the authors had access to the data; con-
tributed to the interpretation of the data, the 
writing of the manuscript, and the review of the 
final version; and were involved in the decision 
to submit the manuscript for publication. The 
first and last authors prepared the initial draft 
of the manuscript. Professional writing assistance 
for all drafts was provided by C4 MedSolutions 
and was paid for by the sponsors. The study 
drugs were provided by Gilead Sciences (ambris-
entan), GlaxoSmithKline (ambrisentan), and Eli 
Lilly (tadalafil). All the authors assume full re-
sponsibility for the accuracy and completeness 
of the data and analyses and for fidelity of the 
manuscript to the study protocol, which is avail-
able at NEJM.org.
Selection of Participants
Participants were 18 to 75 years of age, weighed 
at least 40 kg, had World Health Organization 
(WHO) functional class II or III symptoms of 
pulmonary arterial hypertension, and had re-
ceived a diagnosis of idiopathic pulmonary arte-
rial hypertension, hereditary pulmonary arterial 
hypertension, or pulmonary arterial hypertension 
that was associated with connective tissue dis-
ease, drugs or toxins, human immunodeficiency 
virus (stable disease status), or repaired congeni-
tal heart defects (group 1 of the WHO classifica-
tion of pulmonary hypertension). The diagnosis 
of pulmonary arterial hypertension was estab-
lished by a ruling out of other known causes, 
according to the criteria in current guidelines.2,20 
For each participant, the mean pulmonary ar-
tery pressure was required to be 25 mm Hg or 
greater. Enrolled participants had either not re-
ceived previous treatment with an approved 
therapy for pulmonary arterial hypertension or 
had received treatment for less than 14 days and 
had not received any approved therapy for pulmo-
nary arterial hypertension within 7 days before 
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enrollment. A full set of inclusion and exclusion 
criteria are provided in Table S1 in the Supple-
mentary Appendix. All participants provided 
written informed consent.
A blinded review, performed by the steering 
committee and the sponsors, of demographic 
data from participants enrolled during the first 
6 months of the study showed a relatively high 
prevalence of risk factors for left ventricular dia-
stolic dysfunction, such as coronary artery dis-
ease, diabetes, or hypertension. The decision was 
therefore made to amend the eligibility criteria 
to exclude participants with three or more risk 
factors for left ventricular diastolic dysfunction 
and to set more stringent hemodynamic require-
ments. A comparison of the relevant inclusion 
and exclusion criteria in the initial protocol and 
in the subsequent amendment is provided in 
Table S2 in the Supplementary Appendix.
Study Procedures
Eligible participants were stratified according to 
the underlying cause of pulmonary arterial hyper-
tension (idiopathic or hereditary vs. nonidiopath-
ic) and WHO functional class (II vs. III). Partici-
pants were randomly assigned, in a 2:1:1 ratio 
within each of the stratification strata, to receive 
ambrisentan and tadalafil (combination-therapy 
group), ambrisentan plus placebo (ambrisentan-
monotherapy group), or tadalafil plus placebo 
(tadalafil-monotherapy group). Randomization 
was performed centrally by the study sponsors 
with the use of an interactive voice-response 
system. Ambrisentan and tadalafil were admin-
istered at an increasing dose to a target of 10 mg 
and 40 mg, respectively (Fig. S1 in the Supple-
mentary Appendix).
If a primary end-point event occurred and the 
participant survived and remained in the study, 
investigators had the option either to discontin-
ue the assigned monotherapy and start combina-
tion therapy with ambrisentan and tadalafil or 
to discontinue the assigned combination therapy 
or monotherapy and start prostanoid therapy or 
any other locally available therapy. In all cases, 
blinding of the initial randomized study-group 
assignment was maintained.
Efficacy and safety assessments were per-
formed at the time of screening and at the time 
of randomization; at weeks 4, 8, 16, and 24 and 
every 12 weeks thereafter; and at the visit for the 
final assessment and the visit at the end of the 
study (Fig. S1 in the Supplementary Appendix). 
Laboratory safety assessments were performed 
monthly. A follow-up safety assessment was per-
formed by telephone 30 days after the adminis-
tration of the last dose of study medication.
Outcome Measures
The primary end point in a time-to-event analy-
sis was the first event of clinical failure, which 
was defined as the first occurrence of a compos-
ite end point of death, hospitalization for wors-
ening pulmonary arterial hypertension, disease 
progression, or unsatisfactory long-term clinical 
response. Specific definitions of the components 
of the primary end point are provided in Table 1. 
Supportive analyses were performed for the pri-
mary efficacy end point with the exclusion of the 
unsatisfactory clinical-response component and 
for the first occurrence of each of the individual 
components of the primary end point.
Prespecified secondary efficacy end points were 
the change from baseline to week 24 in N-terminal 
pro–brain natriuretic peptide (NT-proBNP) level, 
6-minute walk distance, WHO functional class, 
and Borg dyspnea index (which measures per-
ceived breathlessness21). We also calculated the 
percentage of participants with a satisfactory 
clinical response at week 24, which was defined 
as an increase of 10% from baseline in the 
6-minute walk distance, with a reduction in 
symptoms to, or maintenance of, WHO func-
tional class I or II and no events of worsening 
clinical condition before or at the week 24 visit. 
Safety assessments included laboratory measure-
ments and evaluation of adverse events.
Statistical Analysis
On the basis of the recommendations of the 
steering committee, we originally projected an 
annual rate of clinical failure events of 10% in the 
combination-therapy group and of 20% in each 
of the monotherapy groups, with this projection 
leading to an estimated hazard ratio for clinical 
failure of 0.47 (i.e., a 53% lower risk of clinical 
failure with combination therapy than with each 
form of monotherapy). As noted above, the pro-
tocol was amended after the start of the study to 
reduce the likelihood of potentially enrolling 
participants with pulmonary hypertension due 
to left ventricular diastolic dysfunction and, after 
a blinded review of the event rate, to increase the 
sample size to preserve power. The primary-
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analysis set comprised all participants who under-
went randomization, received a study drug, and 
met these amended entry criteria (Table S2 in 
the Supplementary Appendix); we also defined a 
modified intention-to-treat analysis set that com-
prised all participants who underwent random-
ization and received a study drug regardless of 
the amended entry criteria. We adopted an event-
driven design; an adjudicated primary end-point 
event was required in 105 participants in the 
primary-analysis set to provide approximately 
97% power to detect a 53% lower risk of clinical 
failure in the combination-therapy group than in 
the pooled-monotherapy group (the two mono-
therapy groups combined), at a type I error rate 
of 5%. Further information regarding the statis-
tical analysis is provided in the Statistical Meth-
ods section in the Supplementary Appendix.
R esult s
Participants
The randomization, treatment, and follow-up of 
participants are shown in Figure S2 in the Sup-
plementary Appendix. A total of 610 participants 
underwent randomization, 5 of whom did not 
receive a study medication. The modified inten-
tion-to-treat population included 605 participants; 
302 were randomly assigned to the combination-
therapy group, 152 to the ambrisentan-monother-
apy group, and 151 to the tadalafil-monotherapy 
group. The primary-analysis set comprised 500 
participants who fulfilled the amended entry 
criteria; 253 were randomly assigned to the 
combination-therapy group, 126 to the ambrisen-
tan-monotherapy group, and 121 to the tadalafil-
monotherapy group.
Baseline characteristics were similar among 
the study groups in the primary-analysis set 
(Table 2). The mean age of the participants was 
54.4 years, and 78% were women. Most partici-
pants had either idiopathic pulmonary arterial 
hypertension or pulmonary arterial hypertension 
due to connective tissue disease, and 69% of par-
ticipants had WHO functional class III symptoms. 
Baseline assessments of disease severity are 
shown in Table 3. The mean pulmonary artery 
pressure among participants was 48.7 mm Hg, and 
the mean 6-minute walk distance was 352.6 m.
Follow-up
In a post hoc analysis of data from the 500 par-
ticipants in the primary-analysis set, the mean 
duration of use of a randomly assigned study 
medication from the start of therapy to the final-
assessment visit was 517 days (550 days in the 
combination-therapy group and 484 days in the 
pooled-monotherapy group, P = 0.03). In an addi-
tional post hoc analysis, the mean duration of 
study participation was 609 days (625 days in 
the combination-therapy group and 593 days in the 
pooled-monotherapy group, P = 0.27).
A total of 64 participants (13%) withdrew from 
the study before having a primary end-point event. 
Of these participants, 8 subsequently had an 
event; that event was included in the analysis of 
Component* Definition
Death from any cause Existence of death certificate
Hospitalization for worsening pulmonary  
arterial hypertension
Any hospitalization for worsening pulmonary arterial hypertension, lung 
or heart and lung transplantation, atrial septostomy, or initiation of 
parenteral prostanoid therapy
Disease progression A decrease of more than 15% from baseline in the 6-minute walk dis-
tance combined with World Health Organization (WHO) functional 
class III or IV symptoms at two consecutive visits separated by at 
least 14 days
Unsatisfactory long-term clinical response Any decrease from baseline in 6-minute walk distance at two consecu-
tive clinic visits after baseline separated by at least 14 days, and WHO 
functional class III symptoms assessed at two clinic visits separated 
by at least 6 months; assessed only among participants who were in 
the study for at least 6 months
*  A clinical end-point committee, whose members were unaware of the study-group assignments and of the identity of 
the investigator, adjudicated all reported clinical events.
Table 1. Components and Definitions of the Primary End Point.
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Characteristic
Combination-
Therapy Group 
(N = 253)
Pooled-
Monotherapy 
Group 
(N = 247)
Ambrisentan-
Monotherapy 
Group 
(N = 126)
Tadalafil-
Monotherapy 
Group 
(N = 121)
Age — yr 54.5±14.3 54.2±14.9 53.9±14.7 54.5±15.2
Female sex — no. (%) 188 (74) 200 (81) 100 (79) 100 (83)
Body-mass index† 27.7±6.3 28.1±6.8 27.6±6.5 28.6±7.2
Race — no. (%)‡
White 233 (92) 213 (86)§ 107 (85) 106 (88)
Nonwhite 20 (8) 34 (14)§ 19 (15) 15 (12)
Region — no. (%)
North America 116 (46) 112 (45) 51 (40) 61 (50)
Europe 129 (51) 128 (52) 72 (57) 56 (46)
Asia-Pacific: Japan and Australia 8 (3) 7 (3) 3 (2) 4 (3)
Coexisting conditions — no. (%)
Hypertension 104 (41) 95 (38) 52 (41) 43 (36)
Diabetes 19 (8) 30 (12) 13 (10) 17 (14)§
Coronary artery disease 16 (6) 4 (2)§ 2 (2)§ 2 (2)§
Classification of pulmonary arterial hyperten-
sion — no. (%)
Idiopathic 127 (50) 138 (56) 72 (57) 66 (55)
Heritable 7 (3) 7 (3) 3 (2) 4 (3)
Associated with connective-tissue disease 103 (41) 84 (34) 44 (35) 40 (33)
Associated with congenital heart disease 5 (2) 4 (2) 1 (1) 3 (2)
Associated with human immunodeficiency 
virus infection
5 (2) 4 (2) 2 (2) 2 (2)
Associated with drug use or toxin exposure 6 (2) 10 (4) 4 (3) 6 (5)
No history of therapy specifically for pulmonary 
arterial hypertension — no. (%)¶
242 (96) 235 (95) 120 (95) 115 (95)
Prior medications — no. (%)
Oxygen 62 (25) 57 (23) 28 (22) 29 (24)
Anticoagulant 78 (31) 76 (31) 30 (24) 46 (38)
Calcium-channel blocker 70 (28) 69 (28) 32 (25) 37 (31)
Diuretic 142 (56) 139 (56) 72 (57) 67 (55)
Aldosterone antagonist 48 (19) 52 (21) 31 (25) 21 (17)
Median time from diagnosis to first adminis-
tration of a study drug — days
20.0 25.0 20.5 29.0§
*  Plus–minus values are means ±SD. The analyses were performed in the primary-analysis set, which comprised all par-
ticipants who underwent randomization, received a study drug, and met amended entry criteria (which excluded partici-
pants with three or more risk factors for left ventricular diastolic dysfunction and set more stringent hemodynamic re-
quirements than those in the original eligibility criteria). All baseline significance testing was performed post hoc. There 
were no significant differences among the groups except as noted.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race was self-reported.
§  P<0.05 vs. the combination-therapy group.
¶  A total of 19 participants (9 in the combination-therapy group and 10 in the pooled-monotherapy group) had received 
previous therapy specifically for pulmonary arterial hypertension that had been discontinued at least 14 days before the 
time of randomization, as required by the protocol. Four participants had missing responses at the time of the initial 
database freeze that were updated to “No” before the final database freeze.
Table 2. Demographic and Baseline Characteristics.*
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the primary end point. Survival status was avail-
able for all but 14 participants (3%) who with-
drew from the study before the final-assessment 
visit, without having had an event; in the analysis 
of the primary end point, data from these par-
ticipants were censored at the time of withdrawal.
Primary Efficacy End Point
A total of 123 participants had a primary end-
point event up to the time of the final-assessment 
visit (Table 4), including 46 (18%) in the combina-
tion-therapy group and 77 (31%) in the pooled-
monotherapy group (43 [34%] in the ambrisen-
tan-monotherapy group and 34 [28%] in the 
tadalafil-monotherapy group). Hospitalization for 
worsening pulmonary arterial hypertension was 
the primary end-point component with the larg-
est observed difference in occurrence between 
the combination-therapy group and the pooled-
monotherapy group (4% vs. 12%) (Table 4). In 
post hoc analyses, rates of hospitalization for 
any cause (calculated with the use of information 
from the serious-adverse-event and adjudication 
datasets) did not differ significantly among the 
groups (Table S3 in the Supplementary Appendix).
The hazard ratios for the primary end point 
were 0.50 (95% confidence interval [CI], 0.35 to 
0.72) for the combination-therapy group versus 
the pooled-monotherapy group (P<0.001 by the 
stratified log-rank test) (Fig. 1A), 0.48 (95% CI, 
0.31 to 0.72) for combination-therapy group ver-
sus the ambrisentan-monotherapy group (P<0.001) 
(Fig. 1B), and 0.53 (95% CI, 0.34 to 0.83) for the 
combination-therapy group versus the tadalafil-
monotherapy group (P = 0.005) (Fig. 1C). A forest 
plot of the adjudicated primary end point (clini-
cal failure) and its components is shown in Figure 
S3 in the Supplementary Appendix.
Variable
Combination-
Therapy Group 
(N = 253)
Pooled-
Monotherapy 
Group 
(N = 247)
Ambrisentan-
Monotherapy 
Group 
(N = 126)
Tadalafil-
Monotherapy 
Group 
(N = 121)
Hemodynamic variables
Arterial blood pressure — mm Hg 90.1±12.9 89.1±11.7 89.5±12.1 88.8±11.3
Right atrial pressure — mm Hg 7.7±4.5 7.9±4.7 7.4±4.6 8.4±4.8
Pulmonary artery pressure — mm Hg 48.1±12.4 49.3±12.6 50.4±12.5 48.1±12.6
Pulmonary-capillary wedge pressure 
— mm Hg
8.4±3.1 8.9±3.4 8.6±3.3 9.3±3.5†
Cardiac index — liter/min/m2 2.41±0.64 2.43±0.71 2.41±0.66 2.45±0.77
Pulmonary vascular resistance  
— dyne/sec/cm5
824.1±467.0 825.7±402.1 852.4±394.7 798.0±409.4
NT-proBNP — ng/liter‡
Median 938.0 1018.0 1171.0 869.0
Interquartile range 328.0–2484.5 334.0–1889.0 383.5–2091.0 297.0–1731.0
6-Minute walk distance — m
Mean 353.5±87.9 351.7±91.8 354.2±92.3 349.2±91.6
Median 357.0 365.5 368.5 363.3
Interquartile range 292.0–425.3 297.5–425.2 310.0–427.5 287.0–421.5
WHO functional class — no. (%)
II 76 (30) 79 (32) 38 (30) 41 (34)
III 177 (70) 168 (68) 88 (70) 80 (66)
*  Plus–minus values are means ±SD. The analyses were performed in the primary-analysis set and include post hoc base-
line significance testing.
†  P = 0.02 for the comparison with the combination-therapy group.
‡  A number of N-terminal pro–B-type natriuretic peptide (NT-proBNP) samples were lost or could not be analyzed. 
Analysis of NT-proBNP was performed on data from 236 participants in the combination-therapy group and 235 in the 
pooled-monotherapy group (120 in the ambrisentan-monotherapy group and 115 in the tadalafil-monotherapy group).
Table 3. Disease Severity at Baseline.*
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End Point
Combination- 
Therapy Group 
(N = 253)
Pooled- 
Monotherapy  
Group 
(N = 247)
Ambrisentan- 
Monotherapy  
Group 
(N = 126)
Tadalafil- 
Monotherapy 
 Group 
(N = 121)
Primary end point
First event of clinical failure — no. of 
 participants (%)
46 (18) 77 (31) 43 (34) 34 (28)
Death 9 (4) 8 (3) 2 (2) 6 (5)
Hospitalization for worsening pulmonary 
arterial hypertension
10 (4) 30 (12) 18 (14) 12 (10)
Disease progression 10 (4) 16 (6) 12 (10) 4 (3)
Unsatisfactory long-term clinical response 17 (7) 23 (9) 11 (9) 12 (10)
Hazard ratio, combination therapy vs. mono-
therapy (95% CI)
Reference 0.50  
(0.35 to 0.72)
0.48  
(0.31 to 0.72)
0.53  
(0.34 to 0.83)
P value — <0.001 <0.001 0.005
Secondary end points
NT-proBNP level†
Percentage change in geometric mean 
from baseline to week 24
−67.2 −50.4 −56.2 −43.8
P value Reference <0.001 0.01 <0.001
Satisfactory clinical response at week 24  
— no. of participants/total no. (%)‡
Yes 91/234 (39) 66/226 (29) 35/113 (31) 31/113 (27)
No 143/234 (61) 160/226 (71) 78/113 (69) 82/113 (73)
Unknown 19/253 (8) 21/247 (9) 13/126 (10) 8/121 (7)
Odds ratio, combination therapy vs. 
monotherapy (95% CI)
Reference 1.56  
(1.05 to 2.32)
1.42  
(0.88 to 2.31)
1.72  
(1.05 to 2.83)
P value — 0.03 0.15 0.03
6-Minute walk distance — m§
Median (IQR) change from baseline to 
week 24
48.98  
(4.63 to 85.75)
23.80 
 (−12.25 to 64.53)
27.00  
(−14.00 to 63.25)
22.70  
(−8.25 to 66.00)
P value Reference <0.001 <0.001 0.003
Change in WHO functional class at week 24 
— no. of participants/total no. (%)§
Improved 94/252 (37) 81/244 (33) 42/124 (34) 39/120 (33)
No change 146/252 (58) 147/244 (60) 73/124 (59) 74/120 (62)
Deteriorated 12/252 (5) 16/244 (7) 9/124 (7) 7/120 (6)
P value Reference 0.24 0.30 0.36
*  The analyses were performed in the primary-analysis set.
†  Data were based on observed cases, with no imputation. A number of NT-proBNP samples were lost or could not be analyzed. Analysis  
of NT-proBNP was performed on data from 204 participants in the combination-therapy group and 199 in the pooled-monotherapy group 
(99 in the ambrisentan-monotherapy group and 100 in the tadalafil-monotherapy group).
‡  Data were based on observed cases, with no imputation.
§  Data were based on last-observation-carried-forward imputation or worst-case imputation. For participants who died or had an adjudicated 
hospitalization (and were unable to perform the test) on or before the date of the week 24 visit, worst-case imputation was used for missing 
data after death or adjudicated hospitalization (for 6-minute walk distance, missing data were imputed as zero; for WHO functional class, 
missing data were imputed as WHO functional class IV). For participants with missing data on 6-minute walk distance or WHO functional 
class before death or adjudicated hospitalization (or if these events did not occur in the case of the participant), last-observation-carried- 
forward imputation was used for missing data. Baseline data were not carried forward. The analysis of the 6-minute walk distance was per-
formed on data from 248 participants in the combination-therapy group and 244 in the pooled-monotherapy group (124 in the ambrisentan-
monotherapy group and 120 in the tadalafil-monotherapy group).
Table 4. Primary and Secondary Efficacy End Points.*
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Results of multiple sensitivity analyses of the 
primary end point are shown in Tables S4 
through S7 and Figure S4 in the Supplementary 
Appendix. The results of these analyses were 
consistent with those of the primary analysis. A 
forest plot of the primary end point in sub-
groups defined according to underlying cause, 
WHO functional class, age, baseline 6-minute 
walk distance, geographic areas, and sex did not 
show any significant interactions between sub-
group and treatment (Fig. S5 in the Supplemen-
tary Appendix).
Secondary Efficacy End Points
Changes from baseline to week 24 in the pre-
specified secondary end points are shown in 
Table 4, and Table S8 in the Supplementary Ap-
pendix. Significant differences were observed in 
favor of combination therapy over pooled mono-
therapy, ambrisentan monotherapy, and tadalafil 
monotherapy with respect to the change from 
baseline in NT-proBNP level, the percentage of 
participants with a satisfactory clinical response 
(with the exception of combination therapy vs. 
ambrisentan monotherapy), and the change from 
baseline in 6-minute walk distance. Overall, the 
percentage of participants in the study groups 
who had an improvement in WHO functional 
class from baseline (Table 4) ranged from 33 to 
37%, and the percentage of those who had no 
change in WHO functional class from baseline 
ranged from 58 to 62%. No significant differ-
ences among the study groups were found. Con-
sequently, according to the prespecified hier-
archical testing procedure (see the Statistical 
Methods section in the Supplementary Appen-
dix), no further statistical comparisons were 
performed.
Safety
The most frequent adverse events are summa-
rized in Table S9 in the Supplementary Appendix. 
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Figure 1. Kaplan–Meier Curves for the Probability  
of a First Adjudicated Primary End-Point Event.
The primary end point in a time-to-event analysis was 
the first event of clinical failure, which was a compos-
ite of death, hospitalization for worsening pulmonary 
arterial hypertension, disease progression, or unsatis-
factory long-term clinical response. The analyses were 
performed in the primary-analysis set, which comprised 
all participants who underwent randomization, received 
a study drug, and met amended entry criteria (which 
excluded participants with three or more risk factors 
for left ventricular diastolic dysfunction and set more 
stringent hemodynamic requirements than those in 
the original eligibility criteria).
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and anemia were more common in the combi-
nation-therapy group than in either monother-
apy group, dizziness was more common in the 
combination-therapy group than in the tadalafil-
monotherapy group, and syncope was more com-
mon in the tadalafil-monotherapy group than in 
the other groups; the incidence of hypotension 
was similar in the three study groups. The rate 
of discontinuation of a study drug and the rate of 
serious adverse events were similar in the three 
study groups (Table S9 in the Supplementary Ap-
pendix). The most common adverse events result-
ing in discontinuation of a study drug were pe-
ripheral edema and dyspnea. The most common 
serious adverse events were worsening of pulmo-
nary arterial hypertension and pneumonia.
Discussion
In the AMBITION trial, the risk of the primary 
end point of the first event of clinical failure was 
50% lower among participants who received ini-
tial combination therapy with ambrisentan and 
tadalafil than among those who received mono-
therapy with either drug. Most previous studies 
of combination therapy for patients with pulmo-
nary arterial hypertension compared the addition 
of a therapy (investigational or approved) with 
placebo in participants already receiving back-
ground treatment with approved drugs (sequen-
tial combination therapy).6-9,11-14 The AMBITION 
trial supports the rationale for targeting multi-
ple pathways in pulmonary arterial hypertension 
and showed that early combination therapy can 
be beneficial.
The older age of our trial participants as com-
pared with those in previous studies8,13 raises the 
possibility that some of the participants enrolled 
in this trial, despite having met the hemody-
namic criteria for pulmonary arterial hyperten-
sion, may have had left ventricular diastolic dys-
function, which is a common condition in patients 
in developed countries starting in the sixth de-
cade of life.22 Therapies for patients with pulmo-
nary arterial hypertension (group 1 of the WHO 
classification) should generally not be used in 
patients with pulmonary hypertension due to left 
ventricular dysfunction (group 2 of the WHO 
classification) and can even be harmful in such 
patients. To limit the potential inclusion of pa-
tients with left ventricular diastolic dysfunction, 
we implemented an amendment excluding par-
ticipants with multiple risk factors for this 
disorder.
The treatment effect with respect to the pri-
mary end point was driven mainly by a lower rate 
of hospitalization for pulmonary arterial hyper-
tension in the combination-therapy group. Hos-
pitalization for worsening pulmonary arterial 
hypertension is costly and is associated with a 
poor prognosis.23-25 Rates of hospitalization for 
any cause did not differ significantly among the 
study groups, although these data were not col-
lected prospectively and are thus subject to some 
uncertainty.
A separation in the curves for the primary 
end point was observed in the primary-analysis 
population at week 24, when an unsatisfactory 
clinical response, the fourth component of clin-
ical failure, could first be assessed. Although the 
curves showed a tendency to converge after 144 
weeks, the number of participants at this time 
point was insufficient to allow a meaningful 
comparison. Alternatively, this convergence after 
144 weeks may suggest a waning beneficial effect 
of initial combination therapy over a longer ob-
servation period.
The analysis of secondary end points provides 
insights into the improvements achieved in the 
first 24 weeks of therapy. The rate of satisfactory 
clinical response, defined as a reduction in symp-
toms to, or maintenance of, WHO functional 
class I or II with improved exercise capacity and 
an absence of clinical events, was significantly 
higher in the combination-therapy group than in 
the pooled-monotherapy group but was not sig-
nificantly higher in the combination-therapy 
group than in ambrisentan-monotherapy group. 
The magnitude of improvement in the 6-minute 
walk distance and of the decrease in NT-proBNP 
levels from baseline to week 24 that was ob-
served in the combination-therapy group is 
similar to or greater than that observed in other 
studies,6-8,11-14,26 in which the placebo-corrected 
treatment effects were amplified because there 
was either no change or a worsening in the con-
dition of the participants receiving placebo.
This study has several limitations. Despite 
improvements in a variety of factors with com-
bination therapy, we found no significant differ-
ence in WHO functional class among the study 
groups at week 24. Second, it is not known 
whether the findings in this study can be ex-
trapolated to the use of other drugs in the same 
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classes or whether initial combination therapy 
with drugs representing other classes of approved 
therapies for pulmonary arterial hypertension 
would produce similar results. Third, our trial 
did not allow us to evaluate the possibility that 
response rates for participants in either of the 
monotherapy groups could have been increased 
if participants receiving one of the agents had 
been switched to the other agent. If some patients 
who do not have a response to one drug class 
have a response to the other drug class, as has 
been hypothesized, then switching classes as a 
treatment strategy might be as effective as com-
bination therapy with potentially fewer side ef-
fects. Addressing this question would require a 
trial with a different design. Finally, it is unclear 
how the protocol amendment to exclude patients 
with risk factors for left ventricular diastolic dys-
function may affect the generalizability of these 
results, although the results of the sensitivity 
analysis that included all participants who re-
ceived a study drug are encouraging in this 
regard.
In conclusion, in the AMBITION study, we 
found that among participants with pulmonary 
arterial hypertension who had not received pre-
vious treatment, the risk of the composite out-
come of clinical failure was significantly lower 
among those who received initial combination 
therapy with ambrisentan and tadalafil than 
among those who received monotherapy with 
either ambrisentan or tadalafil.
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